Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Frank Binder, Independent Consultant (external manufacturing and supply chain management).

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Frank, covering:

 

Getting hooked on supply chain management during his time at Accenture, before joining Novartis’ biopharma business during the early stages of outsourcing and CDMO management.

Deciding to move to Celgene, and feeling liberated by the hands-on, can-do culture of a fast growth company.

The intrigue of joining a highly respected Japanese pharma company to help drive global supply chain alignment.

Common themes in pharma and CDMO relationships, including better planning, clearer communication and secondary sourcing.

How CDMO selection has evolved over the last 10 to 15 years, what has changed and what remains the same, including the role of regionalisation.

The lens he uses to identify genuine, strategic partners he can trust.

 

Dr. Frank Binder is a senior supply chain leader with experience across major pharmaceutical and biopharmaceutical companies in Switzerland, the US and Japan. He is now an independent consultant at GSCA | Global Supply Chain Advisors, having previously held senior roles at Santen, Celgene, Novartis, Roche and Accenture. His expertise spans global supply chain transformation, biologics and API production, CDMO management, international logistics, planning, NPI and SOP/IBP. Frank is a recognised pharmaceutical supply chain thought leader, regularly speaking at industry conferences across Europe, the US and Asia. He holds a doctorate in Physical Chemistry from the University of Berne, with further executive education at Cranfield University, Harvard Business School and INSEAD.

 

Connect with him on LinkedIn.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Stefan Randl, Chief Scientific Officer at Siegfried.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Stefan, covering:

 

How his love of science, combined with a desire to get closer to the business, led him to leave Novartis

His move from science into commercial roles, and how geographic relocations created a compound impact on his career

The decision to leave a large pharma environment and join a smaller CDMO with both drug substance and drug product capabilities

The importance of scientific innovation in creating competitive advantage in a busy and fragmented market

Stefan’s role in shaping capability, R&D and technical investments, and why CDMOs must stay ahead of the curve by backing the areas they truly believe in

How the need for accelerated speed to market is being driven by more assets, higher quality assets and increasingly complex products

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

Stefan Randl (1973) joined Siegfried in January 2025 as Chief Scientific Officer. Prior to joining Siegfried, he spent 16 years at Evonik, where he held various leadership positions in several regions, most recently as Vice President Innovation Management Health Care, based in Frankfurt, Germany, and as Vice President Drug Substance, based in Indiana, US. He also headed Sales & Services for Health Care in Asia, based in Tokyo.  He holds a PhD in Organic Chemistry from the Technische Universität Berlin and is a German citizen.

 

Connect with him on LinkedIn.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Erik Haeffler, CEO at APL.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Erik, covering:

Two decades at AstraZeneca, including being at the forefront of global sourcing and increasingly sophisticated supply chain management in pharma

Managing a highly complex network of more than 100 CDMOs during his time at Meda

Lessons from six years at Recipharm, where he led 4,000 people across 14 manufacturing sites

The unique story behind APL, what attracted him to the CEO role, and how his assumptions about a state owned business were challenged

Implementing a clear strategy for APL’s CDMO business, leading to stronger differentiation and significant growth

The decision to acquire a penicillin facility, and the growth engine now driving APL forward

 

Erik leads APL, a Swedish pharma manufacturing company of 600 people across 5 sites. Being a state owned enterprise with a public policy assignment, APL is a bit of an odd bird on the pharma market. The state assignment comprises pharmacy compounding for the Swedish market, where APL has approx. 80% market share, and also a formal preparedness mission for supply in times of crisis and war. APL is also a fully commercial CDMO with a wide range of capabilities, focusing on a segment that fits into the company's origin in compounding. Erik has more than 30 years in the pharma industry with senior roles in AstraZeneca, Meda and Recipharm. He is also a Board member at Nanologica. 

Connect with him on LinkedIn. 

 

 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

 

Oksana Vodovska, Business Development of Sopharma

Stefan Bouckaert, Quality & Operations Leader, Enabling Business Growth

Nick Wark, Sr. Director / Head of Global External Manufacturing Network, CDMO & Strategic Partnerships, Ferring Pharmaceuticals

 

Your host, Raman Sehgal, discusses the state of contract manufacturing with his guests live from CDMO Live Europe 2026. The event was hosted by PharmaSource and Molecule to Market.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Denis Johnson, Chief Executive Officer at Grand River Aseptic Manufacturing.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Denis, covering:

What his time in the military and the CDMO industry have in common

Why he is passionate about operations, and why operational excellence is the real product CDMOs deliver

His decision to leave a successful leadership role at Catalent and move to the customer side of the industry

Realising his ambition of becoming a CDMO CEO, and why sterile fill finish remains such an attractive area of the market

The case for staying focused in small molecules rather than trying to become a “Swiss Army knife” provider

Why sterile manufacturing continues to be one of the biggest pain points in pharma launches and commercial supply

 

Denis Johnson brings extensive life sciences leadership and manufacturing experience to his role as CEO, including significant prior sterile fill-finish experience. He has led operations and commercial senior leadership roles in the biologics, pharmaceutical, and combination devices for over 25 years. Before being appointed CEO at Grand River Aseptic Manufacturing, his prior roles include Head of Global Manufacturing and Technical Operations at Biogen as well as leadership roles at Catalent, Boston Scientific and Johnson & Johnson. He started his career in the U.S. Army managing logistics and operations.

 

Denis earned a B.S. in Economics from the University of Wisconsin Madison and an MBA from the University of South Carolina.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!